摘要
目的探讨吡非尼酮治疗特发性肺纤维化(IPF)的临床疗效及不良反应。方法将40例处于稳定期的IPF患者分为对照组和试验组,每组20例。对照组给予镇咳、平喘等对症治疗,试验组在此基础上给予吡非尼酮胶囊,0.4 g,口服,每日3次,疗程48周。记录治疗前后两组患者用力肺活量(FVC)、第1秒用力呼气容积(FEV_1)和一氧化碳弥散量(DL_(CO))的变化,观察不良反应发生情况。结果治疗前两组FVC、FEV_1和DL_(CO)无显著差异(P>0.05)。治疗12、24、36周末两组FVC差异无显著意义(P>0.05),治疗48周末对照组FVC低于试验组[(2.31±0.93)L vs.(2.86±0.78)L,P<0.05]。治疗12、24、36、48周末对照组FEV_1均低于试验组(P<0.05),DL_(CO)组间无显著差异(P>0.05),但试验组DL_(CO)下降趋势相对较缓。试验组不良反应发生率为65%(13/20),多为光敏反应、食欲减退、腹部不适、倦怠,程度多为轻至中度,患者均可耐受。结论吡非尼酮治疗IPF具有良好的临床疗效和耐受性。
AIM To investigate the clinical efficacy and adverse reactions of pirfenidone in the treatment of idiopathic puhnonary fibrosis （IPF）. METHODS Forty patients with IPF in stable phase were divided into control group and trial group, 20 cases in each group. The control group was given antitussive, antiasthma and other symptomatic treatment. On the basis of symptomatic treatment, the trial group was given pirfenidonc capsules, 0.4 g, orally, three times daily for 48 weeks. The levels of forced vital capacity （FVC） , forced expiratory volume in 1 second （FEV1） and diffusing capacity of carbon monoxide （DLCO） were recorded before and after the treatment. And the adverse reactions were observed. RESULTS Before the treatment, there were no significant differences in FVC, FEV1 and DLco between the two groups （P 〉 0.05）. After the treatment, there were no significant differences in FVC between the two groups at the end of 12, 24 and 36 week （P 〉 0.05）. The FVC in the control group was lower than that of the trial group （（2.31 ±0.93） L vs. （2.86 ±0.78） L, P 〈 0.05） at the end of 48 week. At the end of 12, 24, 36 and 48 week, the FEVI in the control group was lower than that in the trial group （P 〈 0.05）, but no significant difference was found in DLco between the two groups （P 〉 0.05）. However, the decline trend of the DLCO in the trial group was relatively slow. The incidence of adverse reaction in the trial group was 65% （13/20）. The adverse reaction was mostly photosensitive reaction, loss of appetite, abdominal discomfort and burnout, which was mild to moderate, and the patients were tolerant. CONCLUSION Pirfenidone is efficacy in treating IPF and well tolerated.
作者
雷凯春
岳红梅
周婷婷
LEI Kai-chun1, YUE Hong-mei1, ZHOU Ting-ting2(1. Department of Respiratory Medicine, the First Hospital of Lanzhou l/niversity, Lanzhou GANSU 730000, China; 2. Department of Respiratory Medicine, the Second Hospital of Lanzhou University, Lanzhou GANSU 730000, Chin)
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2018年第3期160-163,共4页
Chinese Journal of New Drugs and Clinical Remedies
